Published in Cancer Cell on December 13, 2011
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity (2014) 1.87
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One (2016) 1.44
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia (2017) 1.40
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest (2013) 1.21
Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17
Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity (2013) 1.07
Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Cancer Res (2013) 1.06
IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol (2013) 1.06
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res (2014) 0.95
Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol (2014) 0.92
Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons? Front Immunol (2013) 0.92
Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer (2014) 0.90
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol (2013) 0.89
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res (2012) 0.88
Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell (2011) 0.86
Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. J Med Genet (2015) 0.85
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Proc Natl Acad Sci U S A (2015) 0.85
Duality of the immune response in cancer: lessons learned from skin. J Invest Dermatol (2014) 0.84
Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. Sci Rep (2015) 0.84
The T cell response to IL-10 alters cellular dynamics and paradoxically promotes central nervous system autoimmunity. J Immunol (2012) 0.84
The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy (2015) 0.83
Functional and Phenotypic Plasticity of CD4(+) T Cell Subsets. Biomed Res Int (2015) 0.83
Characterization of age-associated exhausted CD8(+) T cells defined by increased expression of Tim-3 and PD-1. Aging Cell (2016) 0.82
Inflammatory events during murine squamous cell carcinoma development. J Inflamm (Lond) (2012) 0.82
Chemotherapy, immunity and microbiota--a new triumvirate? Nat Med (2014) 0.82
Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci (2015) 0.81
Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget (2015) 0.81
The modulatory effect of ellagic acid and rosmarinic acid on ultraviolet-B-induced cytokine/chemokine gene expression in skin keratinocyte (HaCaT) cells. Biomed Res Int (2014) 0.81
T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine. Cancer Immunol Res (2015) 0.81
Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr (2016) 0.81
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res (2015) 0.80
The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol (2014) 0.80
The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res (2013) 0.80
Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity. Sci Rep (2016) 0.80
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. PLoS One (2014) 0.79
A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling. Mol Carcinog (2014) 0.79
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discov (2016) 0.78
Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. Oncoimmunology (2015) 0.78
ACC interleukin-10 gene promoter haplotype as a breast cancer risk factor predictor among Jordanian females. Onco Targets Ther (2016) 0.78
Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One (2014) 0.78
IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology (2015) 0.78
Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors. Mediators Inflamm (2016) 0.77
EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes. Oncogenesis (2014) 0.77
The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. Clin Cancer Res (2016) 0.77
Killing from within. Oncoimmunology (2012) 0.75
CD4(+) Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol (2016) 0.75
IL-10: Expanding the Immune Oncology Horizon. Receptors Clin Investig (2015) 0.75
A nested case-control study of 277 prediagnostic serum cytokines and glioma. PLoS One (2017) 0.75
Immunological response in mice bearing LM3 breast tumor undergoing pulchellin treatment. BMC Complement Altern Med (2012) 0.75
Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility. Oncotarget (2017) 0.75
Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol (2016) 0.75
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer (2015) 0.75
Immune cell interplay in colorectal cancer prognosis. World J Gastrointest Oncol (2015) 0.75
Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells. Oncoimmunology (2012) 0.75
PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia. PLoS One (2016) 0.75
PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO. Oncoimmunology (2016) 0.75
Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4(+) T-cells and induction of antitumor CD8(+) T-cell activity. Oncoimmunology (2017) 0.75
Regulatory T-cell heterogeneity and the cancer immune response. Clin Transl Immunology (2017) 0.75
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol (2007) 12.76
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 11.14
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest (2006) 4.77
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med (2012) 4.38
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res (2008) 4.33
Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol (2007) 4.21
Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity (2007) 4.17
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med (2006) 3.36
Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature (2008) 3.09
RORγt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol (2011) 3.03
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med (2009) 2.82
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J (2004) 2.69
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol (2003) 2.17
Axons guided by insulin receptor in Drosophila visual system. Science (2003) 2.10
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res (2006) 2.01
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol (2012) 1.96
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther (2010) 1.93
Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity (2011) 1.87
Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods (2002) 1.85
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun (2002) 1.85
Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci U S A (2003) 1.80
Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol (2007) 1.77
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol (2006) 1.68
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol (2010) 1.56
Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A (2003) 1.54
Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol (2002) 1.51
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther (2011) 1.51
TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol (2006) 1.44
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol (2004) 1.38
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med (2008) 1.37
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 1.36
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther (2005) 1.36
5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther (2010) 1.34
SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One (2012) 1.29
IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res (2012) 1.27
Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol (2002) 1.27
Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics (2009) 1.27
Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest (2013) 1.27
Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther (2010) 1.24
BuildSummary: using a group-based approach to improve the sensitivity of peptide/protein identification in shotgun proteomics. J Proteome Res (2012) 1.24
Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection. Eur J Immunol (2003) 1.23
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol (2004) 1.16
PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem (2006) 1.15
A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun Mass Spectrom (2010) 1.14
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med (2013) 1.13
Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp Neurol (2003) 1.13
Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis (2006) 1.12
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol (2007) 1.10
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorg Med Chem Lett (2007) 1.10
A comparative proteomic strategy for subcellular proteome research: ICAT approach coupled with bioinformatics prediction to ascertain rat liver mitochondrial proteins and indication of mitochondrial localization for catalase. Mol Cell Proteomics (2004) 1.08
Lineage specificity of gene expression patterns. Proc Natl Acad Sci U S A (2004) 1.07
An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. Front Biosci (2002) 1.07
Phosphoproteome analysis of mouse liver using immobilized metal affinity purification and linear ion trap mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.06
The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics (2005) 1.06
AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene (2003) 1.05
Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int J Cancer (2009) 1.04
Gene expression in human neutrophils during activation and priming by bacterial lipopolysaccharide. J Cell Biochem (2003) 1.04
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res (2010) 1.03
Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. Angew Chem Int Ed Engl (2014) 1.02
Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem (2004) 1.02
Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer (2006) 1.02
Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res (2004) 1.02
Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep (2013) 1.01
High-coverage proteome analysis reveals the first insight of protein modification systems in the pathogenic spirochete Leptospira interrogans. Cell Res (2009) 1.01
Daily cost of glaucoma medications in China. J Glaucoma (2007) 1.01